Setting up and sustaining blood and marrow transplant services for children in middle-income economies: an experience-driven position paper on behalf of the EBMT PDWP
-
Published:2020-09-07
Issue:3
Volume:56
Page:536-543
-
ISSN:0268-3369
-
Container-title:Bone Marrow Transplantation
-
language:en
-
Short-container-title:Bone Marrow Transplant
Author:
Faulkner LawrenceORCID, Verna Marta, Rovelli Attilio, Agarwal Rajat KumarORCID, Dhanya Rakesh, Parmar Lalith, Sedai Amit, Kumari Ankita, Ramprakash StalinORCID, Raghuram C. P., Mehta Pallavi, Elizabeth Sandeep, Khalid Sadaf, Batool Aliya, Ghilani Sarah Khan, Fatima Itrat, Zara Tatheer, Marwah Priya, Soni Rajpreet, Trivedi Deepa, Conter Valentino, Canesi MartaORCID, Othman Dosti, Faeq Vian, Kleinschmidt Katharina, Yesillipek Akif, Lam Catherine G., Howard Scott C., Corbacioglu Selim, Jefri Abdulah Al, Bertania Alice, Büchner Jochen, Willasch Andrè, Gibson Brenda, Güngür Tayfun, Ifversen Marianne, Meisel Roland, Müller Ingo, Vetteranta Kim, Veys Paul, Wachowiak Jacek,
Abstract
AbstractSevere blood disorders and cancer are the leading cause of death and disability from noncommunicable diseases in the global pediatric population and a major financial burden. The most frequent of these conditions, namely sickle cell disease and severe thalassemia, are highly curable by blood or bone marrow transplantation (BMT) which can restore a normal health-related quality of life and be cost-effective. This position paper summarizes critical issues in extending global access to BMT based on ground experience in the start-up of several BMT units in middle-income countries (MICs) across South-East Asia and the Middle East where close to 700 allogeneic BMTs have been performed over a 10-year period. Basic requirements in terms of support systems, equipment, and consumables are summarized keeping in mind WHO’s model essential lists and recommendations. BMT unit setup and maintenance costs are summarized as well as those per transplant. Low-risk BMT is feasible and safe in MICs with outcomes comparable to high-income countries but at a fraction of the cost. This report might be of assistance to health care institutions in MICs interested in developing hematopoietic stem cell transplantation services and strengthening context appropriate tertiary care and higher medical education.
Publisher
Springer Science and Business Media LLC
Subject
Transplantation,Hematology
Reference32 articles.
1. Modell B, Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ. 2008;86:480–7. 2. Faulkner L, Uderzo C, Khalid S, Marwah P, Soni R, Yaqub N, et al. ATG vs. thiotepa with busulfan and cyclophosphamide in matched-related bone marrow transplantation for thalassemia. Blood Adv. 2017;1:792–801. 3. La Nasa G, Caocci G, Efficace F, Dessì C, Vacca A, Piras E, et al. Long-term health-related quality of life evaluated more than 20 years after hematopoietic stem cell transplantation for thalassemia. Blood. 2013;122:2262–70. 4. Leelahavarong P, Chaikledkaew U, Hongeng S, Kasemsup V, Lubell Y, Teerawattananon Y. A cost-utility and budget impact analysis of allogeneic hematopoietic stem cell transplantation for severe thalassemic patients in Thailand. BMC Health Serv Res. 2010;10:209–21. 5. Gratwohl A, Baldomero H, Aljurf M, Pasquini MC, Bouzas LF, Yoshimi A, et al. Hematopoietic stem cell transplantation: a global perspective. JAMA J Am Med Assoc. 2010;303:1617–24.
Cited by
19 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|